Clinical Trial: A multicenter prospective observational study of the effectiveness and safety of amivantamab-based regimens (MARIPOSA/MARIPOSA-2) after first-line osimertinib-based therapy in patients with EGFR mutation-positive non-small cell lung cancer (NEJ073) (Japan)

Tokyo, Oct. 14 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063248) titled 'Real-world data on the effectiveness and safety of MARIPOSA/MARIPOSA-2 regimens after first-line osimertinib-based therapy in EGFR-mutated NSCLC: A multicenter prospective observational study (NEJ073)' on Oct. 13.

Study Type: Observational

Primary Sponsor: Institute - NHO Osaka Toneyama Medical Center

Condition: Condition - Advanced non-small cell lung cancer Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - To evaluate the effectiveness and safety of the amivantamab-based regimens (MARIPOSA/MARIPOSA-2) following first-line osimertinib-based therapy (FLAURA or F...